CXCL13 and non-small cell lung carcinoma: Noteworthy, pre-treatment plasma CXCL13, CD40, TRAIL, TNFSF14 and TNFRSF9 were also validated as indicators of irAE for NSCLC patients in Cohort 2 (Fig. 3l-m).